Stephens Inc. AR Reduces Position in Stryker Co. (NYSE:SYK)

Stephens Inc. AR reduced its position in Stryker Co. (NYSE:SYK) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,433 shares of the medical technology company’s stock after selling 467 shares during the quarter. Stephens Inc. AR’s holdings in Stryker were worth $4,476,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SYK. Ritholtz Wealth Management boosted its holdings in Stryker by 6.3% during the 3rd quarter. Ritholtz Wealth Management now owns 5,140 shares of the medical technology company’s stock valued at $1,857,000 after acquiring an additional 306 shares during the period. Retirement Planning Group LLC purchased a new stake in shares of Stryker during the third quarter valued at $249,000. Exchange Traded Concepts LLC grew its holdings in shares of Stryker by 1.9% in the third quarter. Exchange Traded Concepts LLC now owns 5,261 shares of the medical technology company’s stock worth $1,901,000 after purchasing an additional 96 shares during the last quarter. Koshinski Asset Management Inc. increased its stake in Stryker by 4.0% in the 3rd quarter. Koshinski Asset Management Inc. now owns 2,403 shares of the medical technology company’s stock worth $868,000 after buying an additional 92 shares during the period. Finally, McGlone Suttner Wealth Management Inc. bought a new stake in Stryker during the 3rd quarter valued at about $295,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.2 %

Shares of NYSE:SYK opened at $392.15 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $149.49 billion, a P/E ratio of 50.53, a P/E/G ratio of 2.98 and a beta of 0.96. The business’s 50-day moving average is $377.23 and its 200 day moving average is $365.14. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 EPS. On average, research analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SYK. Truist Financial upped their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Citigroup increased their price target on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.